Search

Displaying results 981 - 990 of 1279 in total
  1. Drug

    Implitapide

    go.drugbank.com/drugs/DB04852
    Investigational

    Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.

  2. Drug

    Itepekimab

    go.drugbank.com/drugs/DB16206
    Investigational

    Itepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe

  3. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

  4. Drug

    Pentoxifylline

    go.drugbank.com/drugs/DB00806
    ApprovedInvestigational

    Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claud...

  5. Drug

    MVR-T3011

    go.drugbank.com/drugs/DB17378
    Investigational

    MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1

  6. Drug

    Tagetitoxin

    go.drugbank.com/drugs/DB04788
    Experimental

    Tagetitoxin is a bacterial phytotoxin. It preferentially inhibits eukaryotic RNA polymerase.

  7. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine

  8. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    Kala Pharmaceutical's Inveltys - the first twice-daily (BID) ocular corticosteroid approved for this indication, designed specifically to enhance patient compliance and simplified dosing compared to all

  9. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    [A251385] PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells

  10. Drug

    Dorzolamide

    go.drugbank.com/drugs/DB00869
    ApprovedInvestigational

    Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an...

    Mixtures: Tim-Dor PF, Tim-Dor-Lat